ELTX
Elicio Therapeutics, Inc.
Price Chart
Latest Quote
$3.85
-0.86 (-18.26%)
Current Price
| Previous Close | $4.71 |
| Open | $4.29 |
| Day High | $4.55 |
| Day Low | $3.66 |
| Volume | 5,435,699 |
Stock Information
| Shares Outstanding | 19.09M |
| Total Debt | $14.34M |
| Cash Equivalents | $14.95M |
| Net Income | $-40.19M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $73.48M |
| EPS (TTM) | $-2.37 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $72.87M |
| Income | $-40.19M |
| Book/sh | $-0.08 |
| Cash/sh | $0.78 |
| Employees | 33 |
Financial Ratios
| Quick Ratio | 2.07 |
| Current Ratio | 2.24 |
Returns & Margins
| ROA | -92.41% |
| ROE | -1076.34% |
Ownership
| Insider Ownership | 29.76% |
| Institutional Ownership | 17.01% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.46 |
| P/B | -50.00 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $20.67 |
Technical Indicators
| SMA20 | $10.61 |
| SMA50 | $10.85 |
| SMA200 | $9.94 |
| RSI | 32.45 |
| ATR | 2.3567 |
| Shares Float | 13.19M |
| Short Float | 14.36% |
| Short Ratio | 13.93 |
| Rel Volume | 1.51 |
Performance History
| Week | -72.38% |
| Month | -58.02% |
| Quarter | -67.86% |
| 6 Months | -52.76% |
| YTD | -52.17% |
| Year | -51.57% |
| 3 Years | -75.80% |
| 5 Years | -97.14% |
| 10 Years | -97.74% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.85 | 5,435,700 |
| 2026-06-17 | $4.71 | 51,120,400 |
| 2026-06-16 | $2.76 | 4,871,400 |
| 2026-06-15 | $4.08 | 8,464,300 |
| 2026-06-12 | $14.85 | 125,300 |
| 2026-06-11 | $13.94 | 184,200 |
| 2026-06-10 | $14.30 | 258,700 |
| 2026-06-09 | $14.20 | 127,100 |
| 2026-06-08 | $13.55 | 84,700 |
| 2026-06-05 | $13.26 | 114,900 |
| 2026-06-04 | $13.93 | 294,200 |
| 2026-06-03 | $12.53 | 150,500 |
| 2026-06-02 | $11.49 | 122,100 |
| 2026-06-01 | $12.12 | 91,500 |
| 2026-05-29 | $11.44 | 91,700 |
| 2026-05-28 | $10.61 | 159,900 |
| 2026-05-27 | $10.77 | 116,900 |
| 2026-05-26 | $10.03 | 143,100 |
| 2026-05-22 | $9.95 | 111,400 |
| 2026-05-21 | $9.90 | 115,300 |
| 2026-05-20 | $9.97 | 91,200 |
| 2026-05-19 | $9.17 | 148,500 |
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
đ° Latest News
This Monthly Dividend Powerhouse Is Trading at a Bargain-Bin Valuation
Barchart âĸ 2026-06-16T18:00:02Z
Stocks Settle Sharply Higher as US-Iran Peace Deal Spurs Optimism
Barchart âĸ 2026-06-15T20:36:56Z
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires âĸ 2026-06-15T19:46:51ZELTX Stock Heads For Worst Day Ever â Elicio Therapeutics' Pancreatic Cancer Data Disappoints
Stocktwits âĸ 2026-06-15T18:50:53Z
Top Midday Decliners
MT Newswires âĸ 2026-06-15T18:01:46ZSector Update: Healthcare Stocks Softer Monday Afternoon
MT Newswires âĸ 2026-06-15T17:50:10ZStocks Rally as US-Iran Peace Deal Sinks Oil and Bond Yields
Barchart âĸ 2026-06-15T15:19:00Z
Stocks Soar on US-Iran Peace Agreement
Barchart âĸ 2026-06-15T14:15:30Z
Elicio Therapeutics Shares Plunge After Pancreatic Cancer Study Misses Main Goal (ELTX)
InvestorsHub âĸ 2026-06-15T13:45:32Z
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2026-03-20T13:40:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $1,133,000 | $455,000 | $1,059,000 | $3,597,000 |
| Total Expenses | $37,299,000 | $44,986,000 | $35,745,000 | $23,733,000 |
| Other Income Expense | $-1,915,000 | $-7,234,000 | $1,236,000 | $-943,000 |
| Net Non Operating Interest Income Expense | $-357,000 | $322,000 | $-686,000 | $-3,532,000 |
| Interest Expense Non Operating | $1,133,000 | $455,000 | $1,059,000 | $3,597,000 |
| Operating Expense | $37,299,000 | $44,986,000 | $35,745,000 | $23,733,000 |
| Other Operating Expenses | $-415,000 | - | - | - |
| General And Administrative Expense | $12,811,000 | $11,330,000 | $11,896,000 | $5,630,000 |
| Other Non Operating Income Expenses | - | $-3,502,000 | - | - |
| Total Other Finance Cost | - | $3,502,000 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-39,571,000 | $-51,898,000 | $-35,195,000 | $-28,208,000 |
| Net Interest Income | $-357,000 | $322,000 | $-686,000 | $-3,532,000 |
| Interest Income | $776,000 | $777,000 | $373,000 | $65,000 |
| Normalized Income | $-37,656,000 | $-48,166,000 | $-36,431,000 | $-27,265,000 |
| Net Income From Continuing And Discontinued Operation | $-39,571,000 | $-51,898,000 | $-35,195,000 | $-28,208,000 |
| Total Operating Income As Reported | $-37,714,000 | $-44,986,000 | $-35,745,000 | $-23,733,000 |
| Net Income Common Stockholders | $-39,571,000 | $-51,898,000 | $-35,195,000 | $-28,208,000 |
| Net Income | $-39,571,000 | $-51,898,000 | $-35,195,000 | $-28,208,000 |
| Net Income Including Noncontrolling Interests | $-39,571,000 | $-51,898,000 | $-35,195,000 | $-28,208,000 |
| Net Income Continuous Operations | $-39,571,000 | $-51,898,000 | $-35,195,000 | $-28,208,000 |
| Pretax Income | $-39,571,000 | $-51,898,000 | $-35,195,000 | $-28,208,000 |
| Special Income Charges | $0 | $3,000 | $605,000 | $2,000 |
| Interest Income Non Operating | $776,000 | $777,000 | $373,000 | $65,000 |
| Operating Income | $-37,299,000 | $-44,986,000 | $-35,745,000 | $-23,733,000 |
| Per Share | ||||
| Diluted EPS | $-2.58 | $-4.25 | $-6.96 | $-2.70 |
| Basic EPS | $-2.58 | $-4.25 | $-6.96 | $-2.70 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-35,395,000 | $-46,533,000 | $-34,202,000 | $-22,611,000 |
| Total Unusual Items | $-1,915,000 | $-3,732,000 | $1,236,000 | $-943,000 |
| Total Unusual Items Excluding Goodwill | $-1,915,000 | $-3,732,000 | $1,236,000 | $-943,000 |
| Reconciled Depreciation | $1,128,000 | $1,178,000 | $1,170,000 | $1,057,000 |
| EBITDA (Bullshit earnings) | $-37,310,000 | $-50,265,000 | $-32,966,000 | $-23,554,000 |
| EBIT | $-38,438,000 | $-51,443,000 | $-34,136,000 | $-24,611,000 |
| Diluted Average Shares | $15,312,751 | $12,202,996 | $5,056,225 | $10,463,798 |
| Basic Average Shares | $15,312,751 | $12,202,996 | $5,056,225 | $10,463,798 |
| Diluted NI Availto Com Stockholders | $-39,571,000 | $-51,898,000 | $-35,195,000 | $-28,208,000 |
| Tax Provision | $0 | $0 | $0 | - |
| Gain On Sale Of Ppe | $0 | $3,000 | $0 | - |
| Gain On Sale Of Security | $-1,915,000 | $-3,735,000 | $631,000 | $-945,000 |
| Research And Development | $24,903,000 | $33,656,000 | $23,849,000 | $18,103,000 |
| Selling General And Administration | $12,811,000 | $11,330,000 | $11,896,000 | $5,630,000 |
| Other Gand A | $12,811,000 | $11,330,000 | $11,896,000 | $5,630,000 |
| Other Special Charges | - | - | $-605,000 | $-2,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,636,000 | $-11,312,000 | $11,373,000 | $-102,145,000 |
| Total Assets | $25,862,000 | $28,178,000 | $27,146,000 | $22,664,000 |
| Total Non Current Assets | $6,551,000 | $7,485,000 | $10,798,000 | $11,947,000 |
| Other Non Current Assets | $704,000 | $696,000 | $685,000 | $617,000 |
| Non Current Prepaid Assets | $770,000 | $600,000 | $2,833,000 | $2,833,000 |
| Current Assets | $19,311,000 | $20,693,000 | $16,348,000 | $10,717,000 |
| Other Current Assets | $73,000 | $101,000 | $173,000 | $36,000 |
| Restricted Cash | $0 | $1,178,000 | $722,000 | $1,641,000 |
| Prepaid Assets | $675,000 | $1,796,000 | $2,559,000 | $2,884,000 |
| Cash Cash Equivalents And Short Term Investments | $18,563,000 | $17,618,000 | $12,894,000 | $6,156,000 |
| Cash And Cash Equivalents | $18,563,000 | $17,618,000 | $12,894,000 | $6,156,000 |
| Debt | ||||
| Total Debt | $14,512,000 | $26,040,000 | $6,917,000 | $7,481,000 |
| Long Term Debt And Capital Lease Obligation | $13,501,000 | $25,139,000 | $6,007,000 | $6,789,000 |
| Long Term Debt | $9,407,000 | $20,034,000 | - | - |
| Current Debt And Capital Lease Obligation | $1,011,000 | $901,000 | $910,000 | $692,000 |
| Net Debt | - | $2,416,000 | - | - |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $24,226,000 | $39,490,000 | $15,773,000 | $124,809,000 |
| Total Non Current Liabilities Net Minority Interest | $16,116,000 | $27,967,000 | $6,018,000 | $117,941,000 |
| Derivative Product Liabilities | $2,615,000 | $2,828,000 | $11,000 | $92,000 |
| Current Liabilities | $8,110,000 | $11,523,000 | $9,755,000 | $6,868,000 |
| Current Deferred Liabilities | $0 | $1,169,000 | $694,000 | $1,436,000 |
| Payables And Accrued Expenses | $4,571,000 | $7,141,000 | $6,277,000 | $3,249,000 |
| Payables | $672,000 | $1,038,000 | $4,369,000 | $2,805,000 |
| Accounts Payable | $672,000 | $1,038,000 | $4,369,000 | $2,805,000 |
| Other Current Liabilities | - | - | $25,000 | - |
| Other Non Current Liabilities | - | - | - | $92,000 |
| Equity | ||||
| Common Stock Equity | $1,636,000 | $-11,312,000 | $11,373,000 | $-102,145,000 |
| Total Equity Gross Minority Interest | $1,636,000 | $-11,312,000 | $11,373,000 | $-102,145,000 |
| Stockholders Equity | $1,636,000 | $-11,312,000 | $11,373,000 | $-102,145,000 |
| Gains Losses Not Affecting Retained Earnings | $-127,000 | $-175,000 | $-197,000 | $0 |
| Other Equity Adjustments | $-127,000 | $-175,000 | $-197,000 | - |
| Retained Earnings | $-233,672,000 | $-194,101,000 | $-142,203,000 | $-107,008,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $111,060,000 |
| Other | ||||
| Treasury Shares Number | $14,455 | $14,455 | $14,455 | - |
| Ordinary Shares Number | $17,800,307 | $11,029,382 | $9,603,723 | $8,732,351 |
| Share Issued | $17,814,762 | $11,043,837 | $9,618,178 | $8,732,351 |
| Tangible Book Value | $1,636,000 | $-11,312,000 | $11,373,000 | $-102,145,000 |
| Invested Capital | $11,043,000 | $8,722,000 | $11,373,000 | $-102,145,000 |
| Working Capital | $11,201,000 | $9,170,000 | $6,593,000 | $3,849,000 |
| Capital Lease Obligations | $5,105,000 | $6,006,000 | $6,917,000 | $7,481,000 |
| Total Capitalization | $11,043,000 | $8,722,000 | $11,373,000 | $-102,145,000 |
| Treasury Stock | $150,000 | $150,000 | $150,000 | $0 |
| Additional Paid In Capital | $235,407,000 | $183,004,000 | $153,827,000 | $4,860,000 |
| Capital Stock | $178,000 | $110,000 | $96,000 | $3,000 |
| Common Stock | $178,000 | $110,000 | $96,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $4,094,000 | $5,105,000 | $6,007,000 | $6,789,000 |
| Current Capital Lease Obligation | $1,011,000 | $901,000 | $910,000 | $692,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,528,000 | $2,312,000 | $1,849,000 | $1,491,000 |
| Current Accrued Expenses | $3,899,000 | $6,103,000 | $1,908,000 | $444,000 |
| Net PPE | $5,077,000 | $6,189,000 | $7,280,000 | $8,497,000 |
| Accumulated Depreciation | $-1,756,000 | $-1,552,000 | $-1,231,000 | $-1,123,000 |
| Gross PPE | $6,833,000 | $7,741,000 | $8,511,000 | $9,620,000 |
| Leases | $132,000 | $132,000 | $132,000 | $124,000 |
| Other Properties | $6,443,000 | $7,367,000 | $8,137,000 | $9,137,000 |
| Machinery Furniture Equipment | $258,000 | $242,000 | $242,000 | $359,000 |
| Properties | $0 | $0 | $0 | $0 |
| Construction In Progress | - | - | - | $0 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-36,968,000 | $-37,155,000 | $-32,760,000 | $-22,833,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-36,952,000 | $-37,068,000 | $-32,694,000 | $-22,179,000 |
| Cash Flow From Continuing Operating Activities | $-36,952,000 | $-37,068,000 | $-32,694,000 | $-22,179,000 |
| Operating Gains Losses | $1,915,000 | $7,385,000 | $-927,000 | $947,000 |
| Investing Activities | ||||
| Capital Expenditure | $-16,000 | $-87,000 | $-66,000 | $-654,000 |
| Investing Cash Flow | $-16,000 | $-84,000 | $-32,000 | $-654,000 |
| Cash Flow From Continuing Investing Activities | $-16,000 | $-84,000 | $-32,000 | $-654,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $25,387,000 | $5,635,000 | $6,999,000 | $21,120,000 |
| Financing Cash Flow | $36,695,000 | $42,321,000 | $38,613,000 | $21,202,000 |
| Cash Flow From Continuing Financing Activities | $36,695,000 | $42,321,000 | $38,613,000 | $21,202,000 |
| Net Common Stock Issuance | $25,387,000 | $5,635,000 | $6,999,000 | $0 |
| Common Stock Issuance | $25,387,000 | $5,635,000 | $6,999,000 | $0 |
| Net Other Financing Charges | - | $-549,000 | $21,487,000 | - |
| Repurchase Of Capital Stock | - | - | $-150,000 | $0 |
| Net Preferred Stock Issuance | - | - | $0 | $21,120,000 |
| Preferred Stock Issuance | - | - | $0 | $21,120,000 |
| Other | ||||
| Issuance Of Debt | $0 | $19,727,000 | $10,000,000 | $0 |
| End Cash Position | $19,267,000 | $19,492,000 | $14,301,000 | $8,414,000 |
| Beginning Cash Position | $19,492,000 | $14,301,000 | $8,414,000 | $10,045,000 |
| Effect Of Exchange Rate Changes | $48,000 | $22,000 | $0 | $0 |
| Changes In Cash | $-273,000 | $5,169,000 | $5,887,000 | $-1,631,000 |
| Proceeds From Stock Option Exercised | $11,308,000 | $17,508,000 | $127,000 | $82,000 |
| Net Issuance Payments Of Debt | $0 | $19,727,000 | $10,000,000 | $0 |
| Net Long Term Debt Issuance | $0 | $19,727,000 | $10,000,000 | $0 |
| Long Term Debt Issuance | $0 | $19,727,000 | $10,000,000 | $0 |
| Net PPE Purchase And Sale | $-16,000 | $-84,000 | $-32,000 | $-654,000 |
| Sale Of PPE | $0 | $3,000 | $34,000 | $0 |
| Purchase Of PPE | $-16,000 | $-87,000 | $-66,000 | $-654,000 |
| Change In Working Capital | $-3,445,000 | $3,959,000 | $-57,000 | $-150,000 |
| Change In Other Working Capital | $-1,169,000 | $475,000 | $-742,000 | $1,436,000 |
| Change In Other Current Liabilities | $-901,000 | $-911,000 | $-825,000 | $-535,000 |
| Change In Payables And Accrued Expense | $-2,354,000 | $1,327,000 | $2,239,000 | $820,000 |
| Change In Accrued Expense | $-1,988,000 | $4,658,000 | $2,216,000 | $-305,000 |
| Change In Payable | $-366,000 | $-3,331,000 | $23,000 | $1,125,000 |
| Change In Account Payable | $-366,000 | $-3,331,000 | $23,000 | $1,125,000 |
| Change In Prepaid Assets | $979,000 | $3,068,000 | $-729,000 | $-1,871,000 |
| Other Non Cash Items | $324,000 | $856,000 | $1,136,000 | $3,596,000 |
| Stock Based Compensation | $2,697,000 | $1,452,000 | $1,179,000 | $579,000 |
| Depreciation Amortization Depletion | $1,128,000 | $1,178,000 | $1,170,000 | $1,057,000 |
| Depreciation And Amortization | $1,128,000 | $1,178,000 | $1,170,000 | $1,057,000 |
| Depreciation | $1,128,000 | $1,178,000 | $1,170,000 | $1,057,000 |
| Gain Loss On Investment Securities | $1,915,000 | $7,388,000 | $-427,000 | $945,000 |
| Gain Loss On Sale Of PPE | $0 | $-3,000 | $105,000 | $4,000 |
| Net Income From Continuing Operations | $-39,571,000 | $-51,898,000 | $-35,195,000 | $-28,208,000 |
| Common Stock Payments | - | - | $-150,000 | $0 |
| Repayment Of Debt | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Change In Other Current Assets | - | - | - | $667,245 |
Fetched: 2026-06-18